中华核医学与分子影像杂志最新文献

{"title":"Evaluation of left ventricular function in breast cancer with targeted therapy by gated equilibration ventriculography","authors":"Chen Chen, Bin Sun, Si-long Hu, Xincun Wang, Yongping Zhang, YingJian Zhang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.003","url":null,"abstract":"Objective \u0000To observe the evaluation function of gated equilibration ventriculography for the changes of left ventricular function in breast cancer with targeted therapy. \u0000 \u0000 \u0000Methods \u0000From February 2016 to December 2017, a total of 60 female breast cancer patients (age: 28-65 (48.7±9.4) years) were included prospectively. Patients were divided into 2 groups: lapatinib combined with taxeme-based chemotherapy group (group A; n=25, age: 29-65 (47.8±11.3) years) and lapatinib monotherapy group (group B; n=35, age: 31-62 (51.1±8.5) years). All patients underwent gated equilibration ventriculography before treatment and 6/12 months after treatment. The parameters of left ventricular function including left ventricle ejection fraction (LVEF), peak ejection rate (PER), peak filling rate (PFR), 1/3 ejection fraction (EF), 1/3 filling fraction (FF), time to peak ejection rate (TPER) and time of peak filling rate (TPFR) were observed. Repeated measurement analysis of variance, independent-samples t test and Wilcoxon rank sum test were performed. \u0000 \u0000 \u0000Results \u0000In group A, the PER at 12 months after treatment ((3.11±0.48) end-diastolic volume (EDV)/s) was lower than that before treatment ((3.60±0.62) EDV/s; F=3.447, t=0.60, P 0.05); the PFR at 6 months ((3.07±0.71) EDV/s) and 12 months after treatment ((2.84±0.54) EDV/s) declined significantly compared with that before treatment ((3.57±0.81) EDV/s; F=5.345, t=0.82 and 0.75, both P<0.05). In group B, the PFR at 12 months after treatment ((2.86±0.55) EDV/s) declined significantly compared with that before treatment ((3.23±0.87) EDV/s; F=3.214, t=0.84, P<0.05). The decrease of PFR at 6 months and 12 months after treatment in group A was greater than that in group B (-0.37(-0.78, 0.15) vs -0.13(-0.44, 0.17) EDV/s; z=-1.569, P<0.05). \u0000 \u0000 \u0000Conclusions \u0000The gated equilibration ventriculography can effectively monitor the left ventricular function of breast cancer patients after targeted therapy. PER and PFR may be more sensitive than other parameters to assess heart function changes. The lapatinib combined with taxeme-based chemotherapy can affect diastolic function more and earlier than lapatinib monotherapy. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Molecular targeted therapy; Cardiotoxicity; Ventricular function, left; Gated blood-pool imaging","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"587-590"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42585914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation of a pelvic mass with nuclear medicine functional imaging: a case report","authors":"Huimin Sui, Yaping Luo","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.011","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"620-622"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47424066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application value of 18F-FDG PET/CT in predicting EGFR mutation status in non-small cell lung cancer","authors":"Guotao Yin, Wengui Xu, Xiaofeng Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.012","url":null,"abstract":"Lung cancer is a malignant tumor with the high morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) is the most common type. The emergence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in recent years has provided new treatment option for NSCLC patients. The efficacy of EGFR-TKI is closely related to the EGFR mutation status, but the current detection methods for gene mutation have certain limitations. As a non-invasive method, 18F-fluorodeoxyglucose (FDG) PET/CT shows a certain potential in the detection of EGFR gene mutation status. In this paper, the recent research and progress of PET/CT in predicting the mutation status of EGFR gene are reviewed. \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Mutation; Receptor, epidermal growth factor; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose; Trends","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"623-626"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43316044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary cardiac lymphoma auxiliary diagnosed by 99Tcm-MIBI myocardial perfusion imaging in a patient who underwent permanent pacemaker implantation","authors":"Fangming Chen, Yan Liu, Ping Tang, Chun-yue You, Jianing Cao, Jun Yang, Jianming Ni","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.009","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"616-617"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48027687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary hyperparathyroidism with negative 99Tcm-MIBI dual-phase imaging and positive 18F-FCH PET/CT imaging: a case report","authors":"Huanhuan Li, H. Pang, Xing-guo Jing, D. Duan, Gang Cheng","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.010","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"618-619"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47906119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase analysis of gated myocardial perfusion imaging for early diagnosis of cardiotoxicity caused by anthracyclines in patients with diffuse large B-cell lymphoma","authors":"Chun Qiu, Yan Lin, Weiying Gu, Jian-feng Wang, Xiaoliang Shao, Feifei Zhang, Jiatian Chen, Xiaoxia Li, B. He, Xiao-bao Xie, Zhifang Wu, Yuetao Wang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.004","url":null,"abstract":"Objective \u0000To evaluate the left ventricular systolic synchrony and investigate the early diagnostic value of left ventricular systolic dyssynchrony on cardiotoxicity caused by anthracyclines in patients with diffuse large B-cell lymphoma (DLBCL). \u0000 \u0000 \u0000Methods \u0000Thirty-two patients (22 males, 10 females, age: 22-73(54.4±14.2) years) from June 2016 to January 2019 with confirmed DLBCL and normal gated myocardial perfusion imaging (GMPI) before anthracyclines chemotherapy were enrolled prospectively. GMPI was performed after 6 cycles or more of chemotherapy. Changes of myocardial markers, electrocardiogram (ECG) indicators, left ventricular function indicators including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), peak filling rate (PFR), summed motion score (SMS) and summed thickening score (STS) as well as left ventricular systolic synchrony indicators including phase bandwidth (BW), phase standard deviation (SD) and entropy before and after anthracyclines chemotherapy were analyzed. Paired t test, Wilcoxon signed rank test and χ2 test were used for data analysis. \u0000 \u0000 \u0000Results \u0000Compared with pre-chemotherapy, the left ventricular systolic synchrony indicators were significantly higher than those before chemotherapy (BW: (42.81±11.37)° vs (29.28±8.68)°; SD: (11.65±4.64)° vs (8.79±3.14)°; entropy: (39.84±5.51)% vs (36.19±5.94)%; t values: -9.132 to -3.173, all P 0.05). Of 32 patients, 13 patients (40.62%) had left ventricular systolic dyssynchrony, and the rate of chemotherapy-induced left ventricular systolic dyssynchrony was significantly higher than that of left ventricular dysfunction (15.62%, 5/32; χ2=4.947, P=0.025). All 5 patients with left ventricular dysfunction caused by chemotherapy had left ventricular systolic dyssynchrony. The LVEF of the chemotherapy-induced left ventricular systolic dyssynchrony group was significantly lower than that of the left ventricular systolic synchronization group ((54.54±9.25)% vs (66.79±7.65)%; t=4.087, P<0.01). \u0000 \u0000 \u0000Conclusion \u0000Left ventricular systolic dyssynchrony can be appeared in DLBCL patients after chemotherapy and is significantly earlier than left ventricular dysfunction, which can be an early indicator of cardiotoxicity caused by anthracycline chemotherapy. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, large B cell, diffuse; Drug therapy, combination; Anthracyclines; Ventricular function, left; Myocardial perfusion imaging","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"591-596"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43882561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of BRAFV600E and TERT promoter mutations coexistence in papillary thyroid cancer","authors":"Y. Liu, Min Li, Qiuqin Qian, Peng Wen, F. Shi","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.013","url":null,"abstract":"Papillary thyroid cancer (PTC) is the most common pathological type of thyroid cancer, and its morbidity raises rapidly in the global world. V-raf murine sarcoma viral oncogene homolog B1 (BRAF)V600E mutation and telomerase reverse transcriptase (TERT) promoter mutations are the most common molecular markers of PTC. Nowadays, more and more studies find that the coexistence of BRAFV600E and TERT promoter mutations plays a synergistic role in the invasion and prognosis of PTC. This article reviews the recent advance in the synergism of BRAFV600E and TERT promoter mutations in PTC. \u0000 \u0000Key words: \u0000Thyroid neoplasms; Mutation; Proto-oncogene proteins B-raf; Telomerase; Trends","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"627-631"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42839354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emphasis on the application of radionuclide cardiac imaging in monitoring cardiotoxicity induced by radiotherapy and chemotherapy","authors":"Yuetao Wang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.001","url":null,"abstract":"","PeriodicalId":10099,"journal":{"name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":"577-580"},"PeriodicalIF":0.0,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43141331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening <i>Legionella</i> effectors for antiviral effects reveals Rab1 GTPase as a proviral factor coopted for tombusvirus replication.","authors":"Jun-Ichi Inaba, Kai Xu, Nikolay Kovalev, Harish Ramanathan, Craig R Roy, Brett D Lindenbach, Peter D Nagy","doi":"10.1073/pnas.1911108116","DOIUrl":"10.1073/pnas.1911108116","url":null,"abstract":"<p><p>Bacterial virulence factors or effectors are proteins targeted into host cells to coopt or interfere with cellular proteins and pathways. Viruses often coopt the same cellular proteins and pathways to support their replication in infected cells. Therefore, we screened the <i>Legionella pneumophila</i> effectors to probe virus-host interactions and identify factors that modulate tomato bushy stunt virus (TBSV) replication in yeast surrogate host. Among 302 <i>Legionella</i> effectors tested, 28 effectors affected TBSV replication. To unravel a coopted cellular pathway in TBSV replication, the identified DrrA effector from <i>Legionella</i> was further exploited. We find that expression of DrrA in yeast or plants blocks TBSV replication through inhibiting the recruitment of Rab1 small GTPase and endoplasmic reticulum-derived COPII vesicles into the viral replication compartment. TBSV hijacks Rab1 and COPII vesicles to create enlarged membrane surfaces and optimal lipid composition within the viral replication compartment. To further validate our <i>Legionella</i> effector screen, we used the <i>Legionella</i> effector LepB lipid kinase to confirm the critical proviral function of PI(3)P phosphoinositide and the early endosomal compartment in TBSV replication. We demonstrate the direct inhibitory activity of LegC8 effector on TBSV replication using a cell-free replicase reconstitution assay. LegC8 inhibits the function of eEF1A, a coopted proviral host factor. Altogether, the identified bacterial effectors with anti-TBSV activity could be powerful reagents in cell biology and virus-host interaction studies. This study provides important proof of concept that bacterial effector proteins can be a useful toolbox to identify host factors and cellular pathways coopted by (+)RNA viruses.</p>","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"38 1","pages":"21739-21747"},"PeriodicalIF":0.0,"publicationDate":"2019-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1073/pnas.1911108116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79027535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma","authors":"Yuyan Jiang, Jian Tan, Guizhi Zhang, Z. Meng, Lingyun Xu, Fuhai Zhang","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.004","url":null,"abstract":"ObjectiveTo compare the ablation efficacy and therapy response with 1.1 GBq and 3.7 GBq 131I in postoperative patients with low- and intermediate-risk differentiated thyroid carcinoma(DTC).MethodsA total of 190 patients (43 males, 147 females, age: (45.8±11.1)years) were enrolled from July 2016 to July 2017. Among them, 96 patients received 1.1 GBq 131I and 94 were given 3.7 GBq 131I. Diagnostic whole-body scan was performed 6 months after 131I ablation for treatment response evaluation, and the successful rate of 131I ablation was calculated. χ2 test or Fisher′s exact test was used for data analysis. The cut-off value of 99Tcm-pertechnetate uptake for predicting the successful rate of remnant thyroid ablation in 1.1 GBq group was determined by receiver operating characteristic (ROC) curve analysis.ResultsThe successful ablation rates in 1.1 GBq and 3.7 GBq groups were 79.2%(76/96) and 81.9%(77/94), respectively (χ2=0.229, P>0.05). There was no significant difference in the therapy response between the two groups (χ2=1.371, P>0.05). The successful ablation rate in 3.7 GBq group was higher than that in 1.1 GBq group for patients with stage Ⅲ (5/6 vs 1/7, P=0.029). Moreover, for patients with 5 μg/L<preablative-stimulated thyroglobulin (ps-Tg)≤10 μg/L, the ablation rate in 1.1 GBq group was lower than that in 3.7 GBq group (3/11 vs 10/13, P=0.038). ROC curve analysis showed the cut-off value of 99Tcm-pertechnetate uptake for prediction of the successful ablation rate in 1.1 GBq group was 0.061 5.ConclusionThe low- and intermediate-risk DTC patients with stage Ⅲ disease, 5 μg/L<ps-Tg≤10 μg/L or higher 99Tcm-pertechnetate uptake of remnant thyroid should be given 3.7 GBq other than 1.1 GBq 131I to obtain a better ablation efficacy.Key words: Thyroid neoplasms; Radiotherapy; Iodine radioisotopes; Radiotherapy dosage; Treatment outcome","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"526-531"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41899490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}